Ride to Conquer Cancer: Harry Perkins Institute of Medical Research team takes part in ride


Dianne Beveridge (research officer; on bike) with Michael Epis (research officer), Louis Parker (PhD candidate) and Peter Leedman (director Harry Perkins Institute). Picture: Andrew Ritchie
Dianne Beveridge (research officer; on bike) with Michael Epis (research officer), Louis Parker (PhD candidate) and Peter Leedman (director Harry Perkins Institute). Picture: Andrew Ritchie

A TEAM of researchers from Harry Perkins Institute of Medical Research have taken part in the Ride to Conquer Cancer.

About 20 researchers, researcher support staff, board members and friends took part in the event last weekend.

It is the fifth year the team have taken part in the charity ride, raising more than $1 million for cancer research.

Harry Perkins Institute director Professor Peter Leedman thanked the team from Harry Perkins for their efforts.

“It’s not only the big companies, it’s all the individual people whose lives have been touched by cancer and who decide to make a difference,” he said.

“The researchers strongly believe it is important to ride beside the hundreds of people who are working hard to raise funds for cancer research at the Perkins.

“Each year I ride alongside so many inspiring and courageous people, who have battled cancer or have lost children, mothers or siblings to this insidious disease.”

The ride raised $4 million in total, which will focus on research in hard-to-treat cancers including pancreatic, liver, triple negative breast cancer, prostate cancer and head and neck cancer.

Prof Leedman said the fundraising went towards important cancer research currently being undertaken at Perkins.

He said the fundraising would not be possible without organisations like MACA and Woodside, who support the institute.

“Many riders who participate are cancer survivors, currently battling cancer or have lost a loved one to the disease. The researchers who participate hear their stories and it continues to inspire them in their work,” he said.

“Our researchers are very focused not just on the research, but the outcomes for their patients.”